CN-AML patients have been categorized following the incorporation of their mutational status respective to FLT3 (fms-related tyrosine kinase 3), NPM1 (nucleophosmin), and CEBPA (CCAAT/enhancer-binding protein (C/EBP), alpha) genes in the WHO 2008 classification [17–24]. Here, NPM1 is linked to acute myeloid leukemia.